Focused On-demand Library for Tubulin beta-6 chain

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BUF5

UPID:

TBB6_HUMAN

Alternative names:

Tubulin beta class V

Alternative UPACC:

Q9BUF5; B3KM76; Q9HA42

Background:

Tubulin beta-6 chain, also known as Tubulin beta class V, plays a pivotal role in cell structure and function as the major constituent of microtubules. These cylindrical structures, composed of alpha- and beta-tubulin heterodimers, are essential for various cellular processes including cell division, intracellular transport, and the maintenance of cell shape. The dynamic assembly of tubulin dimers, facilitated by GTP and GDP binding, underpins the functional versatility of microtubules in cellular operations.

Therapeutic significance:

The association of Tubulin beta-6 chain with congenital facial palsy, ptosis, and velopharyngeal dysfunction highlights its potential as a target for therapeutic intervention. Understanding the role of Tubulin beta-6 chain could open doors to potential therapeutic strategies, offering hope for individuals affected by these conditions.